Sarepta Duchenne gene therapy wins broader use from FDA

[cafead]

via The agency on Thursday made the therapy, called Elevidys and sold by biotechnology company Sarepta Therapeutics, available to people with Duchenne who are at least four years of age and have mutations in a specific gene, regardless of whether they can still walk.

article source